Background: There is a need for better, less-invasive disease activity indices that provide a representative assessment of endoscopic disease activity. We developed a new clinical score that incorporates the Harvey-Bradshaw index [HBI] with modified patient-reported outcomes [PRO p ] and physician [clinician]-reported outcomes [PRO c ] and assessed its ability to measure endosopic disease activity in ileocolonic Crohn's disease [CD]. Methods: A cohort of 88 CD patients undergoing colonoscopy was accrued in a prospective fashion. In total, 48 of the subjects were CD cases and 40 had already undergone a post-operative ileocolonic resection [post-op CD]. Each patient underwent multiple, endoscopist-blinded assessments including: HBI score, a PRO p question asking for patient perception of disease activity status, a PRO c question for clinician perception of disease activity status and C-reactive protein [CRP]. Active endoscopic disease was defined as Simple Endoscopic Score for CD [SES-CD] ≥ 3 for CD subjects and Rutgeerts score > i1 for post-op CD subjects. 
Introduction
Management of Crohn's disease [CD] has conventionally been based on symptoms and subjective reporting, but this approach frequently fails to adequately reflect the state of disease activity at the mucosal level. [1] [2] [3] [4] Studies have shown that traditional clinical indices such as the Harvey-Bradshaw index [HBI] and the Crohn's disease activity index [CDAI] , 5, 6 are non-specific and do not correlate well with endoscopic activity. 4, 7 A significant proportion of patients in symptomatic remission have evidence of active mucosal inflammation when a colonoscopy is performed. 1 Recently, the approach to improving outcomes in CD has focused on healing the mucosa and avoiding bowel damage. Treatment towards these targets is thought to result in better outcomes and alteration of the natural history of CD. 8 However, objective assessment of mucosal inflammation and bowel damage typically require invasive and costly procedures such as endoscopy and magnetic resonance/computed tomography enterography [MRE/CTE]. Moreover, there is increasing movement away from reliance on clinical indices such as CDAI and HBI by regulatory authorities in order to improve the ability to assess therapy responses. Of potential increasing value are self-administered questionnaires containing items that are answerable solely by patients, referred to as patientreported outcomes [PROs] , in addition to more objective measures of disease activity such as endoscopy and cross-sectional imaging. [9] [10] [11] [12] In contrast to CD, the Mayo score is more reliable and better reflects actual disease activity in ulcerative colitis [UC], in part because of the incorporation of endoscopic scoring and the inclusion of components such as the physician global assessment [PGA] as a physician [clinician]-reported outcome [PRO c ]. Previous studies have evaluated non-invasive scores in UC which included PRO components where patients were asked whether they thought they were in remission at each visit. 13, 14 Current integrated scores in CD are complicated, not user-friendly and lack validation. There is an unmet need for improved, less-invasive disease activity indices that provide a representative assessment of endoscopic disease activity which include patient-reported outcomes [PRO p ], clinical symptoms and physician [clinician]-reported outcomes [PRO c ]. In this study, we describe the development of a new clinical score for CD, the HBI-PRO, that incorporates the HBI with PRO p and PRO c and we assessed its correlation with endoscopic disease activity in CD using the Simple Endoscopic Score for CD [SES-CD] as the measure of endoscopic disease activity.
Methods

Subjects
A random selection of 88 CD patients between 18 and 75 years of age, attending for a colonoscopy for various indications with confirmed disease based on standard clinical, radiological, endoscopic and histological criteria, and who were managed at Mount Sinai Hospital in Toronto were recruited to this study. questions. The PRO p question was designed to assess the patients' perception of their current disease activity: 'Has your CD been active or inactive during the past two weeks?' Only 'active' or 'inactive' were accepted as possible answers. The PRO c was administered by the treating clinician prior to the colonoscopy based upon the routine pre-endoscopy history in response to the question, 'If you had to scope your patient today, Do you think your patient would have had endoscopically inactive, mild, moderate or severe disease?'. Blood samples for C-reactive protein [CRP] evaluation were also collected on the day of endoscopy. The study was approved by the research ethics board of Mount Sinai Hospital, and all subjects provided written informed consent to participate.
Endoscopic assessment and clinical scoring
Colonoscopies were video recorded and two endoscopists experienced in inflammatory bowel disease reviewed each procedure independently to provide disease activity assessment. Only concordant observations were included in the analysis. The tools used were the SES-CD for CD subjects and the Rutgeerts score for post-operative CD subjects. Active endoscopic disease was defined as SES-CD ≥ 3 16 or Rutgeerts 17 > i1. Specifically, an SES-CD score of 0-3 was defined as inactive disease, 4-6 mild disease, 7-16 moderate disease and >17 severe active disease. These categories were used to define disease activity in an ordered logistic regression model. 16 The endoscopists were blinded to the pre-endoscopic assessments by HBI-PRO and CRP levels. Only subjects with complete ileocolonoscopic examinations were included in this study. The categorical HBI score was also used as an independent variable in all analyses. Specifically, HBI < 5 was defined as clinical remission, HBI between 5 and 7 as mild disease, HBI between 8 and 16 as moderate disease, and HBI > 16 as severe disease.
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Statistical analysis
Basic demographic and clinical characteristics of the cohort were presented in the form of mean and standard deviation for continuous variables and frequency and percentage of the total for categorical variables. Receiver operating characteristic [ROC] curves were generated for several models using logistic regression. In each model, a binary endoscopic score was treated as the dependent variable while a few permutations of independent variables were explored. Different models were compared to one another using a chi-squared test. We also applied an ordered logistic regression model in which the full categorical endoscopic score was used as a dependent variable in order to determine optimal cut-offs for the linear predictors for clinical remission, mild/moderate/severe clinical disease according to the HBI-PRO total score. All statistical analyses were completed in STATA 11.1.
Results
Patient characteristics
A total of 93 subjects were recruited between 2014 and 2015. Five patients were excluded because of non-concordance between the two endoscopists' SES-CD assessment score. A total of 88 subjects were thus eligible to the study of whom 40 were being followed for possible recurrence after ileal resection [post-operative] [ Table 2 ]. When a dichotomized endoscopic score was replaced with a categorical classification in the SES-CD as the outcome variable in the HBI-PRO and HBI-PRO combined with CRP models [Table 3 ], a score range could be determined for inactive, mild, moderate and severe disease. Specifically, for the HBI-PRO model, scores between 0 and 0.47 corresponded to inactive disease, between 0.47 and 1.01 to mild disease, between 1.01 and 3.75 to moderate disease, and greater than 3.75 to severe disease.
The 
Discussion
In this study we developed a new clinical score for CD, the HBI-PRO, which incorporates a PRO p , a PRO c and the HBI with the option to include CRP levels. The HBI-PRO is both more specific and more sensitive to identifying endoscopic activity than the HBI, CRP, PRO p or PRO c alone. Our study clearly demonstrates that the HBI alone is not a reliable, non-invasive clinical score as a proxy for endoscopic disease activity in a routine clinical setting. In contrast to CD, clinical symptoms correlate better with endoscopic disease activity in UC. 14, 20 Furthermore, the Mayo clinical score integrates both clinical symptoms and a physician-reported outcome. Clinical indices in CD, such as the HBI or CDAI, are not wholly reflective of disease activity and mucosal inflammation. [21] [22] [23] Unfortunately, most of our disease treatment paradigms and clinical trial outcomes have been based on studies that rely on such clinical indices to measure outcomes. Treatment strategies based solely on clinical manifestations have failed to modify the course of IBD. [1] [2] [3] [4] It is well known that a significant proportion of patients in symptomatic remission have evidence of active mucosal inflammation when a colonoscopy is performed. Importantly, it has been shown that active mucosal inflammation is one of the best predictors of clinical relapse, disease progression and complications in IBD patients. 8, 24 Major caveats of the current approach of using endoscopy to monitor outcome are the difficulty in implementing it in dayto-day clinical practice and research due to high costs, risks, time demand and, last but not least, patient inconvenience. There is a real need for better, less-invasive disease activity indices that provide a representative assessment of endoscopic disease activity. 28 have already progressed towards PRO questionnaires designed to be completed by patients to measure their perceptions of functional status and well-being. PROs have also begun to find a role in national audits and registers and there is rapidly growing interest in their potential to enable personalized medicine. PROs are also becoming important end points for drug regulatory approval. Since the early 1980s, many scores have been developed for measuring 30 Nevertheless, these PRO questionnaires, among others, are not yet widely accepted and have not been fully validated. Development of an official PRO index and its subsequent validation in IBD according to FDA guidelines will probably take a few years. 31 In this study we proposed a new, simple, short and non-invasive clinical score, the HBI-PRO, which combines the established HBI clinical score with patient-and physician-reported outcome in one question for each. Although the HBI-PRO score was not developed according to FDA guidelines, it could prove very useful in the next few years in clinical practice and research as a more reliable measure of endoscopic disease activity than traditional scoring systems.
The simplicity of the HBI-PRO score, with or without CRP levels, lies in its non-invasive nature and the ease with which it could be obtained by a simple, short patient interview. Even though neither the HBI nor CRP was able to discriminate between inactive and active disease, combining the HBI and PRO p with PRO c greatly improved the model's fidelity.
Our pilot study had several limitations. Firstly, it is acknowledged that the sample size was small and we lacked a validation cohort separate from the cohort used to develop the HBI-PRO. Moreover, in the post-op CD cohort, the HBI-PRO did not significantly improve the model, probably because we used a Rutgeerts score of >i1 to define endoscopy activity although this cut-off was developed to assess recurrence and prognosis and has not been formally validated. Moreover, the HBI-PRO was used in this study to reflect ileocolonic CD as we excluded proximal small bowel CD and perianal disease and used endoscopic assessment as the comparator.
In summary, notwithstanding the limitations outlined, this study demonstrates that the HBI-PRO is a new tool that can easily be incorporated into clinical practice and serve as a useful surrogate for endoscopic disease activity in ileocolonic CD without prior surgery, and can both be used by practising physicians as well as for clinical research.
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